Cancer Pain – Epidemiology – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of cancer pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of cancer pain for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 10 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s cancer pain forecast will answer the following question:

• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of cancer pain over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts seven cancer pain patient populations, as follows:

• Diagnosed prevalent cases of severe cancer pain.
• Diagnosed prevalent cases of breakthrough cancer pain.
• Diagnosed prevalent cases of neuropathic cancer pain.
• Diagnosed prevalent cases of tumor-related neuropathic cancer pain.
• Diagnosed prevalent cases of chemotherapy-related neuropathic cancer pain.
• Diagnosed prevalent cases of neuropathic cancer pain that is related to other causes.
• Diagnosed prevalent cases of metastatic bone pain.

Note: Coverage may vary by country.